| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | BIAF | Common Stock, par value $0.007 | 28.6K | Aug 29, 2022 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | BIAF | Series A Convertible Preferred Stock | Aug 29, 2022 | Common Stock | 286K | $3.67 | Direct | F1, F2 | ||||||
| holding | BIAF | Stock Option (right to buy) | Aug 29, 2022 | Common Stock | 7.14K | $7.70 | Direct | F1, F3 | ||||||
| holding | BIAF | Stock Option (right to buy) | Aug 29, 2022 | Common Stock | 7.14K | $7.70 | Direct | F1, F4 | ||||||
| holding | BIAF | Stock Option (right to buy) | Aug 29, 2022 | Common Stock | 7.14K | $4.20 | Direct | F1, F5 |
| Id | Content |
|---|---|
| F1 | The number of shares of common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer") and the conversion or exercise prices reported in this Form 3 reflect the 1-for-7 reverse stock split of the Issuer's Common Stock, which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO"), as described in the Issuer's registration statement on Form S-1 (File No. 333-264463), which was declared effective by the Securities and Exchange Commission on August 29, 2022 (the "Effective Date"). |
| F2 | The Series A Convertible Preferred Stock (the "Preferred Stock") has no expiration date. Immediately prior to the closing of the IPO on September 6, 2022, the Preferred Stock will automatically convert into fully paid and nonassessable shares of Common Stock at the then-effective conversion rate of the Preferred Stock, which is initially 1-for-7 (as adjusted for the Issuer's 1-for-7 reverse stock split). |
| F3 | Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Meghji under the Issuer's 2014 Equity Incentive Plan (the "EIP") on July 29, 2019. This option vested in 12 monthly installments beginning on August 29, 2019 and is fully vested and exercisable as of the Effective Date. |
| F4 | Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Meghji under the EIP on July 27, 2020. This option vested in 12 monthly installments beginning on August 27, 2020 and is fully vested and exercisable as of the Effective Date. |
| F5 | Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Meghji under the EIP on December 16, 2021. On January 16, 2022, this option began vesting in 12 monthly installments, the first 11 of which are of 595 shares of Common Stock and the last of which is of the remaining 597 shares of Common Stock, subject to Mr. Meghji's continuous service to the Issuer through each vesting date. As of the Effective Date, 4,760 shares of Common Stock underlying this option have vested. The remaining unvested shares of Common Stock will vest immediately prior to the closing of the IPO on September 6, 2022. |
Exhibit List - Exhibit 24.1: Power of Attorney (Mohsin Meghji)